This recombinant monoclonal antibody is developed as a research-grade biosimilar to Ibalizumab-UIYK, targeting the CD4 glycoprotein. CD4 is a transmembrane receptor primarily expressed on T helper cells, regulatory T cells, monocytes, macrophages, and dendritic cells. It functions as a critical co-receptor for the T cell receptor (TCR) complex, facilitating antigen recognition and immune cell activation. CD4 also serves as the primary receptor for HIV-1 entry into host cells, where the virus binds to CD4 before engaging chemokine co-receptors CCR5 or CXCR4. This interaction makes CD4 a central player in HIV pathogenesis and a key target for therapeutic intervention in autoimmune diseases and immunological disorders.
Ibalizumab-UIYK is a humanized IgG4 monoclonal antibody that binds to domain 2 of CD4, blocking HIV-1 entry without interfering with normal immune function. This biosimilar antibody provides researchers with a valuable tool for investigating CD4-mediated processes, HIV entry mechanisms, T cell biology, and immune response modulation. It supports studies in virology, immunology, and therapeutic antibody development.
Email: support@cusabio.com
Distributors Worldwide